In IC-TITAN-TIMI 47, 180 patients with STEMI of less than 6 hour duration eligible for primary angioplasty and treated with standard therapy with ASA, clopidogrel, UFH and eptifibatide will be randomized in approximately 60 sites to treatment of the culprit artery with IC 90 mcg/Kg eptifibatide or placebo in a 2:1 fashion. The primary endpoint of the trial is the improvement in stenosis in the eptifibatide group compared to placebo after IC drug or saline injection.
